Product information and disease descriptionPlace of product in therapyApproaches to treatment
Heterogeneity of treatment effect
15 evidence topics · 18 sources
Intensity of the psychedelic experience and Week 3 response in the phase 2b trial
“The mean intensity of psychedelic effects was dose-related, but distributions of scores for different doses overlapped considerably.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At the 25 mg dose, 5D-ASC dimensions Oceanic Boundlessness (Pearson correlation coefficient r = -0.508) and Visual Restructuralization (r = -0.516), and EBI (r = -0·637) were the variables with the strongest correlation to the Week 3 change from Baseline in MADRS score.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The existence of correlation does not establish causation and exploratory findings require further replication, preferably in larger independent samples.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Therapeutic alliance and Week 3 response in the phase 2b trial
“Change from Baseline to Week 3 MADRS scores showed weaker correlations with pre-dosing therapeutic alliance (-0.178) than with measures of the psychedelic experience: EBI (-0.637), Oceanic Boundlessness (-0.508), and Visual Restructuralization (-0.516).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The effects of the alliance itself on therapeutic efficacy were either limited or absent.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pretreatment clinical characteristics and the psychedelic experience
“Dose was the strongest and most consistent predictor of the psychedelic experience.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Positive affect, lower generalized anxiety symptoms, higher executive functioning, and greater personality disorder symptoms had significant effects on different aspects of the subjective psychedelic experience.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Antidepressant discontinuation before dosing
“Antidepressant drug discontinuation was not related to worsening of depression severity before Baseline.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Psilocybin treatment efficacy and the subjective psychedelic experience did not appear to be compromised by antidepressant drug discontinuation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No significant differences were found between medication discontinued (n = 18) and unmedicated at screening (UAS) (n = 9) groups in clinician rated depression (p = 0.759), self-reported depression (p = 0.215), anxiety (p = 0.178), and suicidality (p = 0.882) symptoms over time, with both groups having clinically significant benefits on all outcomes assessed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Concomitant SSRI treatment in an open-label adjunctive study
“in fact, the response and remission rates were higher in the current study (42% response and remission rates at Week 3 verses 37% and 29%, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Future research should examine whether the outcomes of psilocybin as a monotherapy or as an adjunct to SSRIs remain comparable in a longer term follow up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Severe treatment resistance and comorbid PTSD in an open-label single-site study
“Patients whose illness fails to respond to at least five treatments may be considered to have severely treatment-resistant depression (TRD).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Depressive symptoms were significantly decreased at week 3 (MADRS least-squares mean change=-15.8, 95% CI=-25.4 to -6.3) and Week 12 (MADRS least-squares mean change=-17.2, 95% CI=-25.2 to -9.1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In exploratory analyses, the Oceanic Boundlessness (OB) dimension of the psychedelic experience correlated with post-dosing antidepressant responses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with comorbid PTSD (N=5) showed significantly less antidepressant effect of psilocybin.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Veterans with severe treatment resistance in the same open-label study
“Of 15 participants, 60 % met response and 53 % met remission criteria at Week 3.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Co-morbid PTSD did not significantly influence study outcomes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The psychedelic experience reported in 5D-ASC did not correlate with response.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Number of prior treatment failures: company statements
Early prediction of response from language in the post-dosing session
“While the phase-IIb results are promising, the treatment works for a portion of the population and early prediction of outcome is a key objective as it would allow early identification of those likely to require alternative treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two multinomial logistic regression models were fit to predict responder status at week 3 and through week 12.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cross-validation of these models resulted in 85% and 88% accuracy and AUC values of 88% and 85%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Control-group response in psilocybin trials compared with SSRI and esketamine trials
“MADRS response rates for control treatments in SSRI trials were 14 percentage points higher than in psilocybin trials and in esketamine trials were 23 percentage points higher than in psilocybin trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The poor control treatment outcomes in psilocybin trials suggest that it may not be as broadly effective for depression as estimated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the effect size (standardised mean difference) of high dose psilocybin decreased from large (0.88) to small (0.31) when the reference arm changed from placebo response in the psychedelic trials to antidepressant trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Trial methodology and study size as moderators in meta-analyses
“The subgroup analyses found larger effects, albeit non-significant differences in subgroup heterogeneity, associated with studies that administered psilocybin in bodyweight-adjusted doses and provided longer preparation, dosing, and integration sessions and provided non-manualized psychotherapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Dose-response by type of depression
Regulatory expectations for characterizing variability in response
Payer requests for subgroup data
“Other data participants saw as important included subgroup analyses to elucidate the appropriate treatment population and potential budget impact, and data to assess cost-effectiveness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“They also highlighted that treatment effect is likely more variable given the nature of the treatment and additional, longer-term data will be necessary to increase the predictability of response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote